高钙血症 中国就医指南

Hypercalcemia is a common endocrine disorder characterized by elevated serum calcium concentration—typically defined as total serum calcium >10.5 mg/dL (2.6 mmol/L) or ionized calcium >5.0 mg/dL (1.25 mmol/L)—in adults. It arises not from excess dietary calcium intake, but from dysregulation in calcium homeostasis involving the parathyroid glands, kidneys, bones, and vitamin D metabolism. The most frequent cause is primary hyperparathyroidism (accounting for ~80–90% of outpatient cases), followed by malignancy-associated hypercalcemia (e.g., via PTHrP secretion, osteolytic metastases, or calcitriol overproduction), granulomatous diseases (e.g., sarcoidosis), prolonged immobilization, thiazide diuretic use, and lithium therapy. Pathophysiologically, hypercalcemia disrupts cellular membrane potential, neurotransmitter release, neuromuscular excitability, and renal concentrating ability—leading to multisystem manifestations. Epidemiologically, it affects approximately 0.1–1% of the general population, with prevalence rising sharply with age: up to 2–3% among community-dwelling adults over 60 years and exceeding 5% in hospitalized elderly patients. Women are affected 2–3 times more frequently than men, largely due to higher rates of primary hyperparathyroidism. Key risk factors include advanced age, female sex, chronic kidney disease, vitamin D intoxication, malignancy (especially multiple myeloma, breast, lung, and renal cancers), long-term lithium or thiazide use, and genetic syndromes such as MEN1 or familial hypocalciuric hypercalcemia. Clinically, mild hypercalcemia may be asymptomatic and detected incidentally on routine bloodwork; moderate-to-severe cases present with the classic mnemonic 'stones, bones, groans, moans, and psychiatric overtones': nephrolithiasis or nephrocalcinosis, osteopenia or pathologic fractures, abdominal pain and constipation (due to GI smooth muscle hypotonia), fatigue and muscle weakness, depression, confusion, and even coma at extreme levels (>14 mg/dL). Cardiovascular effects include shortened QT interval, hypertension, and arrhythmias. Quality of life is significantly impaired—even in subclinical cases—due to persistent fatigue, cognitive fog, sleep disturbances, reduced physical stamina, and anxiety about recurrent kidney stones or bone fragility. Chronic hypercalcemia accelerates vascular calcification and increases long-term cardiovascular mortality. Early diagnosis and targeted intervention are essential not only to reverse acute toxicity but also to prevent irreversible renal damage, osteoporosis, and neurocognitive decline. Management requires precise etiological differentiation—via intact PTH, PTHrP, 25-OH and 1,25-(OH)2 vitamin D assays, imaging, and malignancy workup—as treatment strategies differ fundamentally between parathyroid-driven and non-parathyroid causes.

# 高钙血症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：轻中度高钙血症（血钙＜3.0 mmol/L）、无严重心律失常或肾衰竭、病因可逆者（如维生素D中毒、卧床性高钙）。

• •水化+利尿：0.9%生理盐水静脉补液（2–4 L/d）+呋塞米，疗程3–5天；费用区间：1,200–2,800元（含输液耗材、监护、电解质监测×3次）
• •双膦酸盐治疗（唑来膦酸）：单次静脉滴注，起效48–72小时；费用区间：3,500–6,200元（含药费、输注护理、血钙/PTH/肌酐动态监测×5次）
• •降钙素（短期桥接）：皮下注射3–5天；费用区间：1,800–3,000元（含药物、注射耗材、监测）

二、手术/介入治疗方案

适用人群：原发性甲状旁腺功能亢进确诊（PTH↑+血钙↑+颈部超声/⁹⁹ᵐTc-MIBI显像阳性），或难治性高钙危象。

• •微创甲状旁腺切除术（MIP）：术中PTH快速检测+术前定位，住院5–7天；总费用区间：28,000–42,000元（含术前检查：颈部超声+MIBI显像+PTH+25(OH)D+肾功能+心电图，约2,600元；手术费+麻醉+病理+住院）

三、特殊复杂情况处理

适用人群：恶性肿瘤相关高钙（如多发性骨髓瘤、乳腺癌骨转移）、肾衰合并高钙、双膦酸盐抵抗者。

• •地诺单抗皮下注射+水化+透析支持：周期性治疗；月均费用：15,000–22,000元（含药物、血钙/肾功能/骨标志物监测、必要透析支持）

四、方案快速选择指南

• •预算＜5,000元/急性期：首选水化+利尿+电解质监测；
• •预算1.5–4万元/明确甲旁亢：推荐微创甲状旁腺切除术（根治率＞95%）；
• •晚期恶性肿瘤相关：地诺单抗联合多学科支持，优先纳入医保谈判药品目录。